MedTrace Logo

Soy Isoflavonates Versus Placebo on Quality of Life in Menopausal Women

NCT06759350 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-08-28

No results posted yet for this study

Summary

Within the context of the proposed research study, the effect of soy isoflavonoid supplements on the quality of life and coagulation of menopausal women. It has been observed that menopause, as a physiological process, is associated with alterations in the physical, mental and sexual quality of life, making the use of hormone replacement therapy necessary; however, hormone therapy is associated with hypercoagulability, since it has been seen that women have higher levels of thrombogenic microvesicles such as: platelets with a greater probability of causing blood clotting were more likely to present a greater amount of white matter hyperintensities, which appear in the MRI scan.

Conditions

  • Menopause
  • Menopausal Women
  • Soy Isoflavone Effect
  • Quality of Life

Interventions

DIETARY_SUPPLEMENT

Soy isoflavone supplement

2 capsules containing 10 mg natural tocotrienols, 40 mg soy isoflavonoids, 540 mg calcium, vitamin D IU.

OTHER

Control (placebo) group

2 placebo capsules containing a multivitamin compound.

Sponsors & Collaborators

  • Universidad Nacional Autonoma de Honduras

    lead OTHER

Principal Investigators

  • Ricardo A. Gutierrez Ramirez, MD, MSc · Universidad Nacional Autonoma de Honduras

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2025-07-31
Completion
2025-08-01

Countries

  • Honduras

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06759350 on ClinicalTrials.gov